Tech Company Financing Transactions
Lysoway Therapeutics Funding Round
On 6/1/2026, Lysoway Therapeutics landed $3.4 million in funding from The Michael J. Fox Foundation for Parkinson's Research.
Transaction Overview
Company Name
Announced On
6/1/2026
Transaction Type
Debt
Amount
$3,400,000
Round
Undisclosed
Investors
The Michael J. Fox Foundation for Parkinson's Research (Jessica Garcia)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 1st Street 1800
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Lysoway Therapeutics is pioneering the field of lysosomal ion-channel biology and next-generation drug discovery. Using our proprietary screening platforms and structure-guided design technologies, we develop highly brain-penetrant, selective, and potent small-molecule modulators targeting key lysosomal ion channels such as TRPML1 and TMEM175. These ion channels are essential regulators of intracellular signaling and play a central role in maintaining lysosomal health and autophagic flux--critical processes that often break down in age-related neurodegenerative diseases and lysosomal storage disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yongchang Qiu
Vice President
Junsheng Yang
VP - Bus. Development
Xiang Yu
VP - R & D
Valerie Cullen
Browse more venture capital transactions:
Prev: 6/1/2026: Anthropic venture capital transaction
Next: 6/1/2026: MillTech venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs